Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

Raphaël A Itzykson Valeria Santini Sylvain Thépot Lionel AdesCendrine ChaffautAristoteles GiagounidisMargot MorabitoNathalie M DroinMichael LübbertRosa SapenaStanislas NimubonaJean GoasguenEric WattelGina ZiniJose Miguel Torregrosa DiazUlrich GermingAnna Maria PelizzariSophie Park Nadja JäkelGeorgia MetzgerothFrancesco OnidaRobert NavarroAndrea Patriarca Aspassia Stamatoullas Katharina S GötzeMartin PuttrichSandra MossutoEric SolarySilke GloaguenSylvie ChevretFatiha ChermatUwe PlatzbeckerPierre Fenaux

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML (ClinicalTrials.gov identifier: NCT02214407).

Keyphrases

phase iii
open label
clinical trial
acute myeloid leukemia
phase ii
double blind
placebo controlled
bone marrow
study protocol
randomized controlled trial
sickle cell disease
replacement therapy
smoking cessation
drug induced
network analysis